Diabetes drug shows promise for weight loss in Real-World study

NCT ID NCT06427083

Ongoing Disease control Sponsor: Daewoong Pharmaceutical Co. LTD. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study is looking at whether enavogliflozin, a diabetes medication, can help people with type 2 diabetes lose weight. Researchers will track 200 adults over 24 weeks in regular doctor visits. The main goal is to see changes in body weight and BMI, along with safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Enavogliflozin (a diabetes drug that helps lower blood sugar and may aid weight loss)
What this could lead to: If successful, this could show that enavogliflozin is a safe and effective option for weight loss in people with type 2 diabetes, potentially improving overall disease management.
What could go wrong: This is an observational registry study, not a controlled trial, so results may be less reliable. Weight loss effects may be modest, and individual results can vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 2 DIABETES MELLITUS

Contacts and locations

Locations

Kyung Hee University Medical Center

Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.